[Pathophysiology and new treatment of uveitis].
Uveitis is narrow-defined inflammation of the uvea, also clinically include all inflammatory conditions in the eye. Uveitis may occur as a consequence of various causes and background, such as autoimmune diseases, infections, and hematopoietic malignancy. We have to treat uveitis not only controlling the inflammation but also maintaining up the visual function of the eye because the most uveitis is chronic and relapsing inflammatory disorder. Behçét's disease is a systemic disease and results in loss of vision without adequate treatment. Behçét's disease was a representative of vision loss uveitis because Behçét's patient usually had treatment resistance of conventional treatment, such as colchicine and cyclosporine. However, biological therapy with TNF-α, which started from 2007, has revolutionized the treatment strategy of Behçét's disease. It is not too much to say that Behçét's patient is free from fear of vision loss by the dramatic decrease of ocular attach. Biological therapy is not approved as a treatment of uveitis except Behçét's disease. Some protracted cases of Sarcoidosis and Vogt-Koyanagi-Harada disease are resistant to corticosteroid therapy and require new treatment. In this review, we discuss the pathophysiology of uveitis and report new treatment of Behçét's disease by biological therapy.
Department of Ophthalmology, Yamaguchi University Graduate School of Medicine.
Ryoji
R
Yanai
Atsunobu
A
Takeda
Takeru
T
Yoshimura
Koh-Hei
KH
Sonoda
D001528:Behcet Syndrome / Q000628:therapy; D001688:Biological Products / Q000627:therapeutic use; D006801:Humans; D014605:Uveitis / Q000503:physiopathology* / Q000628:therapy*
D001688:Biological Products